Other Scholarly Content

 

Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/defaults/ws859k932

This is the publisher’s final pdf. The published article is copyrighted by American Society for Microbiology and can be found at:  http://aac.asm.org/.

Descriptions

Attribute NameValues
Creator
Abstract
  • Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin- resistant enterococci (VRE) are limited. Prior data suggest that daptomycin at>6 mg/kg of body weight/day may be used to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety of high-dose daptomycin (HD-daptomycin) therapy (>6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics and outcomes. Two hundred forty-five patients were evaluated. Enterococcus faecium was identified in 175 (71%), followed by Enterococcus faecalis in 49 (20%) and Enterococcus spp. in 21 (9%); overall, 204 (83%) isolates were VRE. Enterococcal infections included bacteremia (173, 71%) and intra-abdominal (35, 14%) and bone and joint (25, 10%) infections. The median dosage and duration of HD-daptomycin were 8.2 mg/kg/day (interquartile range [IQR], 7.7 to 9.7) and 10 days (IQR, 6 to 15), respectively. The overall clinical success rate was 89% (193/218), and microbiological eradication was observed in 93% (177/191) of patients. The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR, 2 to 5). The 30-day all-cause mortality rate was 27%, and 5 (2%) patients developed daptomycin-nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult-to-treat infections. No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin may be an option for the treatment of enterococcal infections.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Casapao, A. M., Sakoulas, G., Cosgrove, S. E., Rybak, M. J., Kullar, R., Davis, S. L., . . . Segreti, J. (2013). Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrobial Agents and Chemotherapy, 57(9), 4190-4196. doi:10.1128/AAC.00526-13
Academic Affiliation
Series
Keyword
Rights Statement
Funding Statement (additional comments about funding)
  • A.M.C. has received grant support from Cubist Pharmaceuticals, Forest Laboratories, and the Michigan Department of Community Health. S.L.D. has served on the advisory board of Forest Laboratories. M.J.R. received speaking or consulting honoraria or grant support from Cubist, Forest, and Clinical Therapeutics and is funded in part by NIAID. D.P.L. has served as a consultant for, received grant support from, or served on speakers’ bureaus for Cubist, Astellas, Forest, Theravance, and Rib-X. B.A.P. has received grant support from Cubist. D.A.G. has received grant support from and has served as a consultant or on the speakers’ bureaus for Merck, Cepheid, Forest, Optimer, Cubist, and AdvanDx. J.S. has received grant support from and served on the speakers’ bureau for Cubist. G.S. has received grant support from or served on speakers’ bureaus for Cubist, Forest, and Pfizer. S.E.C. has received grant support from or served as a consultant for Cubist, Astellas, and AdvanDx. C.W.C. and J.J.Z. have no conflicts of interest.
Publisher
Peer Reviewed
Language
Replaces

Relationships

Parents:

This work has no parents.

Items